The interface is intended to aid patients to monitor their progress. The unique selling point is camera function which enables a patient to take an image of themselves at different stages across their treatment journey.
The app also features a calendar that can provide medication and appointment reminders. This is augmented by monthly tips and checklists. Also featured is a progress tracker that comes with ABSORICA (isotretinoin) capsules. This is a prescription-only medicine intended for patients twelve years of age and older to treat severe acne (termed severe recalcitrant nodular acne).
Acne is a condition of various types. Recalcitrant nodular acne (or cystic acne), is the most difficult to treat. Severe recalcitrant nodular acme can leave permanent scars.
Isotretinoin (13-cis-retinoic acid) is a retinoid, meaning it is related to vitamin A, and is found in small quantities naturally in the body. In most countries, isotretinoin can only be prescribed by dermatologists or specialist physicians.
The drug can cause side effects, including birth defects, and serious mental health problems. The ABSORICA Tracker App has been designed to allow patients to monitor the treatment process, and to understand what the elements are for successful treatment.
The main functionality of the app is:
My Progress Tracker: Allows users to visually see how their skin is developing over time.
My Plan: Includes monthly tips and checklists to keep patients on track for success.
Medication Reminders: Used to remind patients to never miss a dose.
Appointment Reminders: Helps ensure that patients see their healthcare professional on time.
Medication Guide: Includes important information about ABSORICA.
This new app was launched on October 23, 2017 via both Apple and Google services.
Commenting on the app, dermatologist Dr. Hillary Baldwin said to Mobi Health News: “In today’s mobile-centric world people are using their phones to track everything, from their steps to their food intake. The development of an App is useful to those who are willing to fully commit themselves to the ABSORICA treatment process.”
